c

Baricitinib for dermatitis

17th May 2021 by Dr Louise Hudman

Baricitinib for dermatitis

NICE has released a new guideline on the use of Baricitinib in moderate to severe atopic dermatitis. Baricitinib is a Janus kinase (JAK) inhibitor.

As JAK is essential for certain cytokine signalling, by disrupting JAK, you disrupt cytokine signalling and thus disrupt the body’s immune response.

It will be used fourth line (after normal GP treatments, phototherapy and 1 other systemic immunosuppressant).

Read more

No credit card details needed – it takes two minutes.

Join free trial

Login

Already a member? Login to view this content.

Login

Related content

"I feel strongly that sessional GPs need an organisation solely focussed on representing their interests."

Dr Tim Cantor, GP

See the full list of features within our NASGP membership plans

Membership